EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS

Normative Disclosure, Honest Communication

Select category

ANNOUNCEMENTS SHAREHOLDER INFORMATION

Select time

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Date

Title

File

Times

2023-03-08

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

1846

2023-02-24

NOTICE OF BOARD MEETING

1801

2023-02-22

UPDATE ON DISCLOSEABLE TRANSACTION AMENDMENT AGREEMENT TO THE CO-DEVELOPMENT LICENSE AGREEMENT WITH SHANGHAI HENLIUS BIOTECH, INC. FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION

1860

2023-02-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST DOSE COMPLETED IN THE UNITED STATES IN AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

1861

2023-01-10

1861

2022-10-13

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON SkQ1

1972

2022-08-23

INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2022

1918

2022-08-23

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022

2042

2022-08-09

NOTICE OF BOARD MEETING

2071

2022-07-06

2050

2022-04-29

AMENDED AND RESTATED ARTICLES OF ASSOCIATION

2029

2022-04-29

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 29 APRIL 2022

1995

2022-03-25

NOTICE OF ANNUAL GENERAL MEETING

2000

2022-03-25

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 29 APRIL 2022 (or any adjournment thereof)

1985

2022-03-25

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, AMENDMENTS TO ARTICLES OF ASSOCIATION, ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING

2141

2022-03-23

PROPOSED AMENDMENTS TO ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION

2152

2022-03-22

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2021

2233

2022-03-22

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

2315

2022-03-10

NOTICE OF BOARD MEETING

2203

2021-11-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST VISIT COMPLETED IN A PHASE 3 CLINICAL STUDY IN THE PRC IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

2174

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT